Trial Begins on Novel Stroke Therapy

Preclinical studies have shown that treatment with an oxygenated fluorocarbon nutrient emulsion (OFNE) several hours after initiation of a severe ischemic stroke can limit brain damage. A phase I safety trial is now under way.

The OFNE, called Revoxyn, bypasses the blocked blood vessels and delivers oxygen and nutrients directly to the injured brain tissue, says the developer, Neuron Therapeutics, Inc. (Malvern, PA, USA). In the brain, Revoxyn acts to reduce the amount of swelling and damage to brain tissue caused by a sudden interruption in blood flow. The first person to receive this investigational therapy was recently treated at Thomas Jefferson University Hospital (Philadelphia, PA, USA). The novel drug and its delivery system are the outgrowth of research at Thomas Jefferson University.

"Stroke treatment represents an enormous unmet medical need,” said Dr. Rodney Bell, principal investigator and director of the Jefferson Stroke Center. "The approach Neuron Therapeutics is taking is remarkably different from anything that has been tried before in

that it involves direct delivery of oxygen and nutrients to oxygen-starved brain tissue.”



Related Links:
Neuron Therapeutics